Next Generation Antibody Technologies- Seattle Genetics Leads the Way Monoclonal Antibody Technology has revolutionized medicine. Since 1986, more than 20 Antibody drugs have been approved, with sales of $26 Billion.
Incyte Pharmaceuticals: JAK it Up Incyte Pharmaceuticals has one of the most promising pipelines in the small to mid-cap space. It has two very promising compounds in development, INCB18424 for.
The Promise Behind Celldex Celldex shares climbed steadily in the months leading up to the release of its ASCO abstracts, rising from $4.71 at the start of the year and.
The Women’s Health Initiative (WHI), a study that demonstrated several lethal side-effects of hormone replacement therapy (HRT), has left many pharmaceutical companies scrambling to advance alternative therapies to meet the.
Several weeks ago, DepoMed (NASDAQ:DEPO), a specialty pharmaceutical company, announced positive phase 3 trial results for the treatment of Post Herpetic Neuralgia (‘PHN’) with DM1796. But DepoMed’s news of success.
Vivus Pharmaceuticals shocked the health-care industry earlier this year when it announced positive phase III results for it’s new obesity miracle drug. The drug, dubbed Qnexa, is a combination of.
Pharmaceutical M&A is still robust. Rumors are spreading that Warner Chilcott (NASDAQ:WCRX) will purchase Proctor & Gamble’s (NYSE:PG) prescription drug unit as early as tomorrow. The price tag is rumored.
Women who are experiencing menopausal symptoms have few treatment options. According to two studies conducted by researchers at Northwestern University and University of Illinois, two commonly used over-the-counter (OTC) remedies.
Depomed (NASDAQ:DEPO), a specialty pharmaceutical company, reported positive updates in it’s most recent 10Q regarding it’s phase 1 clinical trial for the treatment of Parkinson’s disease with DM-1992, a novel.
Metformin, a first-line diabetes treatment, lowers the risk of pancreatic cancer by 62%. According to a study conducted by Donghui Li, Ph.D from the University of Texas M.D. Anderson Cancer.
During menopause, women experience many symptoms associated with the natural change in hormone levels. Hot flashes and sexual dysfunction are the most prevalent symptoms, and if untreated can lead to.
Today, Wyeth (NYSE:WYE) announced that their compound, bazedoxifene/conjugated-estrogens, significantly reduces the severity and frequency of menopausal hot flashes. Although the use of hormones has been associated with several potentially lethal.
Merck acquires non-exclusive license for Acuform technology from Depomed Merck plans to use technology to expand it’s diabetes portfolio Signifies the extended release diabetes market is growing more competitive Pharmaceutical.
Rumors are buzzing in the pharma sector. Pfizer (NYSE:PFE) may be considering a takeover of Abdi Ibrahim, Turkey’s largest pharmaceutical company, demonstrating Pfizer’s shift from domestic markets to emerging markets..
Earlier this month, I suggested that there is a huge unmet need, and substantial market opportunity, for a potential product that will treat menopausal symptoms. We recommended several Women’s Health companies..
Pharmacuetical Giant, Johnson & Johnson, is taking a minority stake in Ireland’s Elan 18% stake for $1 Billion USD Elan’s (NYSE:ELN) wish came true. The Irish company attracted a Big.
After the Women’s Health Initiative there is an opportunity for new non-hormonal treatments for menopausal symptoms Some estimates believe this market may be up to $8 Billion USD Before the.
Reuters reported that Solvay has drawn up a shortlist of potential bidders for it’s drug business. The start of a second round of the divestment process is supposed to imply.
Recently, an article from Seeking Alpha has got me scratching my head! The title: “Santarus: Business Fundamentals Improving”, which was written by an analyst from Zack’s. The article highlighted recent.